Paper Details

  1. Home
  2. Paper Details

De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.

Author: BoyettJames M, BrennerTimothy L, DervieuxThierry, EvansWilliam E, HancockMichael L, HonYuen Y, PuiChing-Hon, RellingMary V, RibeiroRaul C, RiveraGaston K, SandlundJohn T, ZhouYinmei

Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Methotrexate (MTX) and mercaptopurine (MP) are effective antileukemic agents that work by inhibiting de novo purine synthesis (DNPS). This study investigated the pharmacodynamic differences between these agents in children with acute lymphoblastic leukemia (ALL). The study found that MTX plus MP produced greater antileukemic effects and DNPS inhibition than MP alone, with full inhibition more frequent after HDMTX.
Paper Details　
Original Abstract of the Article :
Methotrexate (MTX) and mercaptopurine (MP) are widely used antileukemic agents that inhibit de novo purine synthesis (DNPS) as a mechanism of their antileukemic effects. To elucidate pharmacodynamic differences among children with acute lymphoblastic leukemia (ALL), DNPS was measured in leukemic bla...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12149204

データ提供：米国国立医学図書館（NLM）

Targeting De Novo Purine Synthesis: A Powerful Approach to Fight Leukemia

Acute lymphoblastic leukemia (ALL) is a serious cancer that affects the bone marrow, and current treatments often rely on drugs that inhibit de novo purine synthesis (DNPS), a crucial metabolic pathway for cell growth. This research investigated the effectiveness of two common antileukemic agents, methotrexate (MTX) and mercaptopurine (MP), in inhibiting DNPS and achieving antileukemic effects. The study found that combining MTX and MP resulted in significantly greater DNPS inhibition and antileukemic effects compared to MP alone. Importantly, patients with full DNPS inhibition experienced greater antileukemic effects than those with partial or no inhibition.

The Promise of Targeted Therapy in Leukemia

This research demonstrates the power of targeting specific metabolic pathways like DNPS in combating leukemia. It suggests that combining MTX and MP could be a more effective therapeutic strategy, particularly in patients with a higher rate of DNPS. This study contributes to a growing body of knowledge supporting the use of personalized medicine in cancer treatment.

Beyond the Lab: Understanding Leukemia and Treatment

Leukemia, like a desert storm, can be unpredictable and destructive. Understanding the specific characteristics of leukemia, including the rate of DNPS, is crucial for guiding treatment decisions and maximizing the chances of successful treatment. This research highlights the importance of considering individual differences in response to therapy and the potential benefits of personalized treatment strategies.

Dr. Camel's Conclusion

Targeting DNPS in leukemia is like using a powerful compass to navigate the vast and treacherous desert of cancer treatment. This research provides crucial insights into the effectiveness of different treatment strategies, showing that combining MTX and MP can be a potent tool in our arsenal against this formidable disease. It's a reminder that even in the face of a seemingly insurmountable challenge, there is always hope for finding effective treatments that target the specific needs of individual patients.

Date :
  1. Date Completed 2002-09-12
  2. Date Revised 2021-02-06
Further Info :

Pubmed ID

12149204

DOI: Digital Object Identifier

S0006-4971(20)59315-4

Related Literature

Article Analysis
・Effects of mercaptopurine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.